HAMBURG, Germany -- Paris-listed pharmaceutical manufacturer Euroapi is phasing out production of 13 medical ingredients, leaving Europe dependent on cheaper Chinese imports for its most commonly used drugs such as paracetamol.
As part of the pullback, Euroapi, formerly a unit of industry major Sanofi, will sell its manufacturing plants in the Italian city of Brindisi and the U.K. town of Haverhill by the end of 2027. A spokesperson told Nikkei Asia the moves were necessary because of "decreasing or stagnant markets and increasing competition from Asian players."
